Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors

Published: 1 October 2025| Version 1 | DOI: 10.17632/brxp657w22.1
Contributors:
Zehao Luo, Yuming Sun, Ziyu Guo, Furong Zeng, Guangtong Deng

Description

Supplementary materials for the article titled “Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors” Patient Consent: All data were de-identified and publicly available, thus the study was exempt from institutional review board approval and informed consent. Finding: Overall, our findings suggest that ICIs may confer greater benefit in KPMCC than in UPMCC.

Files

Institutions

  • Xiangya Hospital Central South University
  • Central South University

Categories

Merkel Cell Carcinoma, Survival Analysis, Cohort Study, Immune Checkpoint Inhibitor

Funders

Licence